logo

For the Inventor, By the Inventor

Osaka, Japan

Mitsubishi Pharma Corporation


USPTO Granted Patents = 73

% Expired Patents = 65.8



Forward Citations = 730

Loading Chart...
Loading Chart...

194 inventors (with patents filed for the assignee):

goldMedal Mourad Saady (19 out of 44 patents)

silverMedal Alistair Lochead (19 out of 75 patents)

bronzeMedal Philippe Yaiche (19 out of 43 patents)

4.  Franck Slowinski (14 out of 19 patents)

5.  Alain Nedelec (8 out of 18 patents)

6.  Thierry Gallet (6 out of 13 patents)

7.  Masayoshi Uehata (6 out of 11 patents)

8.  Séverine Marguerie (6 out of 8 patents)

9.  Kenji Chiba (5 out of 23 patents)

10.  Kunitomo Adachi (4 out of 14 patents)

11.  Takanobu Kuroita (4 out of 16 patents)

12.  Adrien Tak Li (4 out of 14 patents)

13.  Patrick Andre Lardenois (4 out of 21 patents)

14.  Naoki Sugiyama (3 out of 46 patents)

15.  Hiroyuki Satoh (3 out of 86 patents)


Core Competencies:
Pharmaceutical Compositions
GSK3 Inhibitors
Neurodegenerative Treatments
Therapeutic Agents
Amyotrophic Lateral Sclerosis
Prophylaxis
Injection Formulations
Protein Production
Pyrimidine Derivatives
Cancer Remedies
Monoclonal Antibodies
Gene Encoding

73 patents:

1. 8324283 - Solid pharmaceutical compositions comprising a SIP receptor agonist and a sugar alcohol (2012-12-04),
2. 8093256 - Use of 8-substituted-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one derivatives (2012-01-10),
3. 7781440 - [object Object] (2010-08-24),
4. 7659387 - Transgenic mammals introduced a Period 1 promoter that confers rhythmical expression (2010-02-09),
5. 7566720 - [object Object] (2009-07-28),
6. 7547705 - [object Object] (2009-06-16),
7. 7507746 - Enantiomer of tenatoprazole and the use thereof in therapy (2009-03-24),
8. 7507743 - Substituted 8'-pyridinyl-dihydrospiro-[cycloalkyl]-pyrimido[1,2-a] pyrimidin-6-one and 8′-pyrimidinyl-dihydrospiro-[cycloalkyl]-pyrimido[1,2-a] pyrimidin-6-one derivatives (2009-03-24),
9. 7465737 - [object Object] (2008-12-16),
10. 7462621 - Use of substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo[1,2-a] pyrimidin-5(1H)one derivatives as therapeutic agents (2008-12-09),
11. 7452897 - Use of substituted 2-(diaza-bicyclo-alkyl)-pyrimidone derivatives for the treatment of neurodegenerative diseases (2008-11-18),
12. 7429663 - 7-(Pyrimidin-4-yl)-Imidazo[1,2-a]Pyrimidin-5(1H)-ones as GSK3β inhibitors (2008-09-30),
13. 7427615 - 3-substituted-4-pyrimidone derivatives (2008-09-23),
14. 7396915 - Monoclonal antibody and gene encoding the same, hybridoma, pharmaceutical composition, and diagnostic reagent (2008-07-08),
15. 7393853 - [object Object] (2008-07-01),
Company Overview
Mitsubishi Pharma Corporation, headquartered in Osaka, Japan, specializes in the development and manufacturing of pharmaceutical compositions. The company focuses on innovative therapeutic agents, particularly in the realm of neurodegenerative diseases, including treatments for amyotrophic lateral sclerosis. Their research encompasses GSK3 inhibitors and advanced injection formulations, alongside efforts in protein production, aiming to enhance prophylactic measures and improve patient outcomes in various medical conditions.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

73 Patents

#149 in Osaka

#1,379 in Japan

#10,263 in the World

Osaka, JP
Osaka, Japan

Mitsubishi Pharma Corporation

Forward Citations = 730

194 inventors:

goldMedal Mourad Saady (19 out of 44 patents)

silverMedal Alistair Lochead (19 out of 75 patents)

bronzeMedal Philippe Yaiche (19 out of 43 patents)

4.  Franck Slowinski (14 out of 19 patents)

5.  Alain Nedelec (8 out of 18 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Mitsubishi Pharma Corporation. Retrieved from https://idiyas.com/company/mitsubishi-pharma

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…